Ignite Creation Date:
2025-12-24 @ 7:40 PM
Ignite Modification Date:
2025-12-29 @ 8:37 PM
Study NCT ID:
NCT05580003
Status:
COMPLETED
Last Update Posted:
2024-11-21
First Post:
2022-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008874', 'term': 'Midazolam'}, {'id': 'D000077266', 'term': 'Moxifloxacin'}], 'ancestors': [{'id': 'D001569', 'term': 'Benzodiazepines'}, {'id': 'D001552', 'term': 'Benzazepines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D024841', 'term': 'Fluoroquinolones'}, {'id': 'D042462', 'term': '4-Quinolones'}, {'id': 'D015363', 'term': 'Quinolones'}, {'id': 'D011804', 'term': 'Quinolines'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publication until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Part 1 and Part 6: From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 and 52 days respectively); Part 2 and Part 5: From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 and 65 days respectively); Part 3 and Part 4: From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 and 47 days respectively)', 'description': 'Safety population included all participants randomly assigned to study intervention, who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.', 'eventGroups': [{'id': 'EG000', 'title': 'Part 1: Placebo (Suspension), Fasted', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 4, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Part 1: Placebo (Suspension), Fed', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.', 'otherNumAtRisk': 2, 'deathsNumAtRisk': 2, 'otherNumAffected': 1, 'seriousNumAtRisk': 2, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Part 1: PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Part 1: PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Part 1: PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 0, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Part 1: PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 3, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG006', 'title': 'Part 1: PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 0, 'seriousNumAtRisk': 5, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Part 1: PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.', 'otherNumAtRisk': 5, 'deathsNumAtRisk': 5, 'otherNumAffected': 1, 'seriousNumAtRisk': 5, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 1, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 0, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.', 'otherNumAtRisk': 4, 'deathsNumAtRisk': 4, 'otherNumAffected': 2, 'seriousNumAtRisk': 4, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG012', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.', 'otherNumAtRisk': 1, 'deathsNumAtRisk': 1, 'otherNumAffected': 0, 'seriousNumAtRisk': 1, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG013', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.', 'otherNumAtRisk': 3, 'deathsNumAtRisk': 3, 'otherNumAffected': 2, 'seriousNumAtRisk': 3, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG014', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 4, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG015', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 1, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG016', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 1, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG017', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.', 'otherNumAtRisk': 12, 'deathsNumAtRisk': 12, 'otherNumAffected': 4, 'seriousNumAtRisk': 12, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG018', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG019', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 4, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG020', 'title': 'Part 5: PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.', 'otherNumAtRisk': 13, 'deathsNumAtRisk': 13, 'otherNumAffected': 11, 'seriousNumAtRisk': 13, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG021', 'title': 'Part 5: Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.', 'otherNumAtRisk': 13, 'deathsNumAtRisk': 13, 'otherNumAffected': 10, 'seriousNumAtRisk': 13, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG022', 'title': 'Part 6: Placebo (Suspension), Fasted', 'description': 'Participants received Placebo oral suspension at 0 and 1 hours on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.', 'otherNumAtRisk': 23, 'deathsNumAtRisk': 23, 'otherNumAffected': 0, 'seriousNumAtRisk': 23, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG023', 'title': 'Part 6: PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.', 'otherNumAtRisk': 23, 'deathsNumAtRisk': 23, 'otherNumAffected': 0, 'seriousNumAtRisk': 23, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG024', 'title': 'Part 6: Moxifloxacin 400 mg, Fasted', 'description': 'Participants received 400 mg Moxifloxacin oral tablet and placebo at 0 and 1 hour respectively on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.', 'otherNumAtRisk': 24, 'deathsNumAtRisk': 24, 'otherNumAffected': 0, 'seriousNumAtRisk': 24, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Flatulence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 2}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Lipase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Urine output decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Defaecation urgency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Glossodynia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Vessel puncture site bruise', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Skin laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Hypoaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 1}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Urinary retention', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Rhinorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Pseudofolliculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 2}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Abdominal distension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Haematochezia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Dysmenorrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 1}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Urine output increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Paraesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 9}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 9}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Haemoptysis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 2}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}, {'term': 'Urticaria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 2, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 5, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 4, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 1, 'numAffected': 0}, {'groupId': 'EG013', 'numAtRisk': 3, 'numAffected': 0}, {'groupId': 'EG014', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG015', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG016', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG017', 'numAtRisk': 12, 'numAffected': 0}, {'groupId': 'EG018', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG019', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG020', 'numAtRisk': 13, 'numAffected': 0}, {'groupId': 'EG021', 'numAtRisk': 13, 'numAffected': 1}, {'groupId': 'EG022', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG023', 'numAtRisk': 23, 'numAffected': 0}, {'groupId': 'EG024', 'numAtRisk': 24, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'Placebo (Suspension), Fed', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG006', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG007', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '1', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 1: Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'Placebo (Suspension), Fed', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG006', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG007', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}, {'value': '2', 'groupId': 'OG006'}, {'value': '2', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)', 'description': 'Laboratory parameters included: (lymphocytes less than (\\<) 0.8\\*lower limit of normal \\[LLN\\] \\[10\\^3 per millimeter cube {mm3}\\], lymphocytes/leukocytes \\<0.8\\*LLN \\[percentage {%}\\], neutrophils \\<0.8\\*LLN \\[10\\^3/mm3\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], monocytes/leukocytes greater than (\\>) 1.2\\*upper limit of normal \\[ULN\\] \\[%\\], partial thromboplastin time \\>1.1\\*ULN \\[seconds\\]), chemistry (bicarbonate \\<0.9\\*LLN \\[milliequivalents per liter {mEq/L}\\], creatine kinase \\>2.0\\*ULN \\[units per liter {U/L}\\], lipase \\>1.5\\*ULN \\[U/L\\]), and urinalysis (urine hemoglobin greater than or equal to \\[\\>=\\] 1, leukocyte esterase \\>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'Placebo (Suspension), Fed', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG006', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG007', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'title': 'SBP value < 90 mmHg', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '1', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'SBP Change >= 30 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'SBP Change >= 30 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'DBP Value < 50 mmHg', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'DBP Change >= 20 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'DBP Change >= 20 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'PR Value < 40 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}, {'title': 'PR Value > 120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 2 of each period', 'description': 'Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\\>=) 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 beats per minute (bpm), value \\> 120 bpm.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}, {'value': '5', 'groupId': 'OG006'}, {'value': '5', 'groupId': 'OG007'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'Placebo (Suspension), Fed', 'description': 'Participants who received a single dose of placebo as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG006', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG007', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}, {'value': '0', 'groupId': 'OG006'}, {'value': '0', 'groupId': 'OG007'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 2 of each period', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG004', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG005', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 2: Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG004', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG005', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)', 'description': 'Laboratory parameters included: hematology (lymphocytes/leukocytes \\>1.2\\*ULN \\[%\\], neutrophils \\<0.8\\*LLN \\[10\\^3/mm3\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\]), chemistry (urate \\>1.2\\*ULN \\[milligrams per deciliter\\] {mg/dL}), and urinalysis (ketones \\>=1, urine hemoglobin \\>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG004', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG005', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 12', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG004', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'OG005', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 12', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'title': 'AUCinf', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42970', 'spread': '35', 'groupId': 'OG000'}, {'value': '44140', 'spread': '38', 'groupId': 'OG001'}, {'value': '28430', 'spread': '28', 'groupId': 'OG002'}, {'value': '42930', 'spread': '43', 'groupId': 'OG003'}, {'value': '46170', 'spread': '27', 'groupId': 'OG004'}]}]}, {'title': 'AUClast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '42540', 'spread': '35', 'groupId': 'OG000'}, {'value': '43570', 'spread': '37', 'groupId': 'OG001'}, {'value': '27750', 'spread': '29', 'groupId': 'OG002'}, {'value': '41620', 'spread': '41', 'groupId': 'OG003'}, {'value': '35930', 'spread': '54', 'groupId': 'OG004'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG003'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '101.29', 'ciLowerLimit': '95.71', 'ciUpperLimit': '107.18', 'estimateComment': 'A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.', 'groupDescription': 'AUCinf', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '102.74', 'ciLowerLimit': '97.28', 'ciUpperLimit': '108.50', 'estimateComment': 'A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.', 'groupDescription': 'AUCinf', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG003'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '97.83', 'ciLowerLimit': '91.32', 'ciUpperLimit': '104.80', 'estimateComment': 'A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.', 'groupDescription': 'AUClast', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '102.41', 'ciLowerLimit': '95.60', 'ciUpperLimit': '109.70', 'estimateComment': 'A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.', 'groupDescription': 'AUClast', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.', 'unitOfMeasure': 'Nanogram*Hour per milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '9354', 'spread': '18', 'groupId': 'OG000'}, {'value': '6934', 'spread': '35', 'groupId': 'OG001'}, {'value': '4590', 'spread': '21', 'groupId': 'OG002'}, {'value': '6284', 'spread': '38', 'groupId': 'OG003'}, {'value': '5008', 'spread': '47', 'groupId': 'OG004'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG003'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '67.18', 'ciLowerLimit': '58.13', 'ciUpperLimit': '77.65', 'estimateComment': 'A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '74.12', 'ciLowerLimit': '64.14', 'ciUpperLimit': '85.67', 'estimateComment': 'A mixed effect model was used with sequence, period and treatment as fixed effect and participant nested within sequence as random effect. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.', 'unitOfMeasure': 'Nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'PRIMARY', 'title': 'Part 4: Percentage of Total Dose Administered Recovered in Urine', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '12.6', 'spread': '4.7', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to 144 hours post-dose', 'description': 'The percentage of total dose administered recovered in urine was reported in this outcome measure.', 'unitOfMeasure': 'Percentage dose excreted', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 4: Percentage of Total Dose Administered Recovered in Feces', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '88.9', 'spread': '10', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to 144 hours post-dose', 'description': 'The percentage of total dose administered recovered in feces was reported in this outcome measure.', 'unitOfMeasure': 'Percentage dose excreted', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '101.5', 'spread': '7.7', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to 144 hours post-dose', 'description': 'The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.', 'unitOfMeasure': 'Percentage dose excreted', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 5: Maximum Observed Concentration (Cmax) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '33.71', 'spread': '34', 'groupId': 'OG000'}, {'value': '30.20', 'spread': '28', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'Cmax of midazolam was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '94.30', 'spread': '26', 'groupId': 'OG000'}, {'value': '79.85', 'spread': '31', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.', 'unitOfMeasure': 'Nanogram*Hour per milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 6: Number of Participants With TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants received Placebo oral suspension at 0 and 1 hours on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG001', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG002', 'title': 'Moxifloxacin 400 mg, Fasted', 'description': 'Participants received 400 mg Moxifloxacin oral tablet and placebo at 0 and 1 hour respectively on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 6: Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '22', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants received Placebo oral suspension at 0 and 1 hours on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG001', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG002', 'title': 'Moxifloxacin 400 mg, Fasted', 'description': 'Participants received 400 mg Moxifloxacin oral tablet and placebo at 0 and 1 hour respectively on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)', 'description': 'Laboratory parameters included: hematology (lymphocytes \\<0.6\\*LLN \\[10\\^3/mm3\\], lymphocytes/leukocytes \\>1.2\\*ULN \\[%\\], neutrophils \\<0.8\\*LLN \\[10\\^3/mm3\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], basophils/leukocytes \\>1.2\\*ULN \\[%\\], eosinophils/leukocytes \\>1.2\\*ULN \\[%\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\], partial thromboplastin time \\>1.1\\*ULN \\[seconds\\], prothrombin time \\>1.1\\*ULN \\[seconds\\]), chemistry (bicarbonate \\<0.9\\*LLN \\[mEq/L\\], creatine kinase \\> 2.0\\*ULN \\[U/L\\], lipase \\> 1.5\\*ULN \\[U/L\\], urobilinogen \\>=1 \\[ehrlich units/deciliter\\] {EU/dL}) and urinalysis (urine hemoglobin \\>=1, leukocyte esterase \\>=1, ketones \\>=1, bacteria \\>20 \\[per low power field\\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'PRIMARY', 'title': 'Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants received Placebo oral suspension at 0 and 1 hours on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG001', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG002', 'title': 'Moxifloxacin 400 mg, Fasted', 'description': 'Participants received 400 mg Moxifloxacin oral tablet and placebo at 0 and 1 hour respectively on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'title': 'SBP value < 90 mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}]}]}, {'title': 'SBP change >= 30 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'SBP change >= 30 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'DBP value < 50 mmHg', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'DBP change >= 20 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'DBP change >= 20 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'Pulse rate value < 40 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}, {'title': 'Pulse rate value > 120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 6 of each period', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'PRIMARY', 'title': 'Part 6: Number of Participants According to Categorization of ECG Data', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}, {'value': '23', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Suspension), Fasted', 'description': 'Participants received Placebo oral suspension at 0 and 1 hours on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG001', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}, {'id': 'OG002', 'title': 'Moxifloxacin 400 mg, Fasted', 'description': 'Participants received 400 mg Moxifloxacin oral tablet and placebo at 0 and 1 hour respectively on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'title': 'QTCF interval, aggregate 450 msec < Value <= 480 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}, {'title': 'QTCF interval, aggregate 30 msec < Change <= 60 msec', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 6 of each period', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \\< value \\<= 480 msec and QTcF interval, aggregate 30 msec \\< change \\<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 1: Maximum Observed Concentration (Cmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '2269', 'spread': '51', 'groupId': 'OG000'}, {'value': '6235', 'spread': '20', 'groupId': 'OG001'}, {'value': '3223', 'spread': '13', 'groupId': 'OG002'}, {'value': '17420', 'spread': '36', 'groupId': 'OG003'}, {'value': '34420', 'spread': '12', 'groupId': 'OG004'}, {'value': '34670', 'spread': '36', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 1: Time for Cmax (Tmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.00', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '1.50'}, {'value': '0.792', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.50'}, {'value': '1.25', 'groupId': 'OG002', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '0.500', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.500', 'groupId': 'OG004', 'lowerLimit': '0.500', 'upperLimit': '1.05'}, {'value': '1.00', 'groupId': 'OG005', 'lowerLimit': '0.550', 'upperLimit': '1.50'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '10890', 'spread': '47', 'groupId': 'OG000'}, {'value': '34580', 'spread': '25', 'groupId': 'OG001'}, {'value': '27080', 'spread': '25', 'groupId': 'OG002'}, {'value': '83490', 'spread': '36', 'groupId': 'OG003'}, {'value': '160700', 'spread': '33', 'groupId': 'OG004'}, {'value': '185700', 'spread': '17', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.', 'unitOfMeasure': 'Nanogram*hour per milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '15.14', 'spread': '51', 'groupId': 'OG000'}, {'value': '12.48', 'spread': '19', 'groupId': 'OG001'}, {'value': '6.445', 'spread': '13', 'groupId': 'OG002'}, {'value': '11.61', 'spread': '36', 'groupId': 'OG003'}, {'value': '11.49', 'spread': '12', 'groupId': 'OG004'}, {'value': '8.672', 'spread': '36', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.', 'unitOfMeasure': 'Nanogram per milliliter per milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '72.61', 'spread': '47', 'groupId': 'OG000'}, {'value': '69.17', 'spread': '25', 'groupId': 'OG001'}, {'value': '54.16', 'spread': '25', 'groupId': 'OG002'}, {'value': '55.64', 'spread': '35', 'groupId': 'OG003'}, {'value': '53.53', 'spread': '33', 'groupId': 'OG004'}, {'value': '46.43', 'spread': '17', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.', 'unitOfMeasure': 'Nanogram*hour/milliliter/milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '11250', 'spread': '53', 'groupId': 'OG000'}, {'value': '35950', 'spread': '25', 'groupId': 'OG001'}, {'value': '28120', 'spread': '28', 'groupId': 'OG002'}, {'value': '85320', 'spread': '34', 'groupId': 'OG003'}, {'value': '166100', 'spread': '34', 'groupId': 'OG004'}, {'value': '189400', 'spread': '19', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '74.99', 'spread': '53', 'groupId': 'OG000'}, {'value': '71.81', 'spread': '25', 'groupId': 'OG001'}, {'value': '56.23', 'spread': '28', 'groupId': 'OG002'}, {'value': '56.86', 'spread': '34', 'groupId': 'OG003'}, {'value': '55.33', 'spread': '35', 'groupId': 'OG004'}, {'value': '47.34', 'spread': '19', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.', 'unitOfMeasure': 'Nanogram*hour/milliliter/milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 1: Terminal Half-Life (t1/2) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.534', 'spread': '0.50659', 'groupId': 'OG000'}, {'value': '13.88', 'spread': '10.838', 'groupId': 'OG001'}, {'value': '15.95', 'spread': '8.4657', 'groupId': 'OG002'}, {'value': '10.84', 'spread': '6.1747', 'groupId': 'OG003'}, {'value': '18.79', 'spread': '14.234', 'groupId': 'OG004'}, {'value': '13.05', 'spread': '7.3974', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '86.87', 'spread': '48', 'groupId': 'OG000'}, {'value': '209.5', 'spread': '101', 'groupId': 'OG001'}, {'value': '366.1', 'spread': '50', 'groupId': 'OG002'}, {'value': '242.9', 'spread': '80', 'groupId': 'OG003'}, {'value': '367.4', 'spread': '87', 'groupId': 'OG004'}, {'value': '358.7', 'spread': '44', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\\*kel).', 'unitOfMeasure': 'Liter (L)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 1: Apparent Clearance (CL/F) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 150 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 150 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG001', 'title': 'PF-07817883 500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG002', 'title': 'PF-07817883 500 mg (Suspension), Fed', 'description': 'Participants who received a single dose of PF-07817883 500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fed conditions were included.'}, {'id': 'OG003', 'title': 'PF-07817883 1500 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 1500 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG004', 'title': 'PF-07817883 3000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 3000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}, {'id': 'OG005', 'title': 'PF-07817883 4000 mg (Suspension), Fasted', 'description': 'Participants who received a single dose of PF-07817883 4000 mg as an oral suspension on Day 1 of either Period 1, 2 or 3 under fasted conditions were included.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.33', 'spread': '53', 'groupId': 'OG000'}, {'value': '13.93', 'spread': '25', 'groupId': 'OG001'}, {'value': '17.79', 'spread': '28', 'groupId': 'OG002'}, {'value': '17.58', 'spread': '35', 'groupId': 'OG003'}, {'value': '18.09', 'spread': '35', 'groupId': 'OG004'}, {'value': '21.13', 'spread': '19', 'groupId': 'OG005'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.', 'unitOfMeasure': 'Liter per hour (L/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3582', 'spread': '20', 'groupId': 'OG000'}, {'value': '8470', 'spread': '39', 'groupId': 'OG001'}, {'value': '24100', 'spread': '22', 'groupId': 'OG002'}, {'value': '8381', 'spread': '12', 'groupId': 'OG003'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4234', 'spread': '7', 'groupId': 'OG000'}, {'value': '9112', 'spread': '14', 'groupId': 'OG001'}, {'value': '27530', 'spread': '22', 'groupId': 'OG002'}, {'value': '8260', 'spread': '18', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3492', 'spread': '15', 'groupId': 'OG000'}, {'value': '7852', 'spread': '21', 'groupId': 'OG001'}, {'value': '23420', 'spread': '14', 'groupId': 'OG002'}, {'value': '7306', 'spread': '25', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram/milliliter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.759', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.775', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.500', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.50'}, {'value': '1.00', 'groupId': 'OG003', 'lowerLimit': '1.00', 'upperLimit': '1.05'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.859', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '1.02'}, {'value': '0.500', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '0.500'}, {'value': '0.500', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.500', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.00'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.500', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.500', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.00'}, {'value': '0.500', 'groupId': 'OG002', 'lowerLimit': '0.500', 'upperLimit': '0.500'}, {'value': '0.533', 'groupId': 'OG003', 'lowerLimit': '0.500', 'upperLimit': '1.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '14760', 'spread': '26', 'groupId': 'OG000'}, {'value': '36440', 'spread': '27', 'groupId': 'OG001'}, {'value': '108400', 'spread': '15', 'groupId': 'OG002'}, {'value': '36880', 'spread': '22', 'groupId': 'OG003'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '18460', 'spread': '15', 'groupId': 'OG000'}, {'value': '36300', 'spread': '10', 'groupId': 'OG001'}, {'value': '114000', 'spread': '22', 'groupId': 'OG002'}, {'value': '37680', 'spread': '29', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '17180', 'spread': '10', 'groupId': 'OG000'}, {'value': '34960', 'spread': '8', 'groupId': 'OG001'}, {'value': '103900', 'spread': '18', 'groupId': 'OG002'}, {'value': '34650', 'spread': '29', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.', 'unitOfMeasure': 'Nanogram*hour per milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '389.3', 'spread': '15', 'groupId': 'OG000'}, {'value': '734.5', 'spread': '15', 'groupId': 'OG001'}, {'value': '2598', 'spread': '47', 'groupId': 'OG002'}, {'value': '716.0', 'spread': '47', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '425.7', 'spread': '12', 'groupId': 'OG000'}, {'value': '865.9', 'spread': '22', 'groupId': 'OG001'}, {'value': '2315', 'spread': '35', 'groupId': 'OG002'}, {'value': '585.5', 'spread': '28', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': '12 hours on Day 5 and Day 10', 'description': 'C12 of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '17.93', 'spread': '20', 'groupId': 'OG000'}, {'value': '14.15', 'spread': '39', 'groupId': 'OG001'}, {'value': '16.07', 'spread': '22', 'groupId': 'OG002'}, {'value': '14.00', 'spread': '12', 'groupId': 'OG003'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '21.18', 'spread': '7', 'groupId': 'OG000'}, {'value': '15.20', 'spread': '13', 'groupId': 'OG001'}, {'value': '18.35', 'spread': '22', 'groupId': 'OG002'}, {'value': '13.76', 'spread': '18', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '17.47', 'spread': '15', 'groupId': 'OG000'}, {'value': '13.07', 'spread': '21', 'groupId': 'OG001'}, {'value': '15.61', 'spread': '14', 'groupId': 'OG002'}, {'value': '12.20', 'spread': '25', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.', 'unitOfMeasure': 'Nanogram/milliliter/milligram (ng/mL/mg)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '73.94', 'spread': '26', 'groupId': 'OG000'}, {'value': '60.70', 'spread': '27', 'groupId': 'OG001'}, {'value': '72.25', 'spread': '15', 'groupId': 'OG002'}, {'value': '61.44', 'spread': '22', 'groupId': 'OG003'}]}]}, {'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '92.46', 'spread': '15', 'groupId': 'OG000'}, {'value': '60.49', 'spread': '10', 'groupId': 'OG001'}, {'value': '76.20', 'spread': '23', 'groupId': 'OG002'}, {'value': '62.82', 'spread': '29', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '86.04', 'spread': '10', 'groupId': 'OG000'}, {'value': '58.28', 'spread': '8', 'groupId': 'OG001'}, {'value': '69.43', 'spread': '18', 'groupId': 'OG002'}, {'value': '57.78', 'spread': '29', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.', 'unitOfMeasure': 'Nanogram*hour/milliliter/milligram', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1542', 'spread': '15', 'groupId': 'OG000'}, {'value': '3022', 'spread': '10', 'groupId': 'OG001'}, {'value': '9515', 'spread': '22', 'groupId': 'OG002'}, {'value': '3140', 'spread': '29', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1434', 'spread': '10', 'groupId': 'OG000'}, {'value': '2914', 'spread': '8', 'groupId': 'OG001'}, {'value': '8672', 'spread': '18', 'groupId': 'OG002'}, {'value': '2890', 'spread': '29', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.', 'unitOfMeasure': 'Nanogram/milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1.250', 'spread': '28', 'groupId': 'OG000'}, {'value': '0.9972', 'spread': '18', 'groupId': 'OG001'}, {'value': '1.054', 'spread': '9', 'groupId': 'OG002'}, {'value': '1.022', 'spread': '7', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1.163', 'spread': '18', 'groupId': 'OG000'}, {'value': '0.8962', 'spread': '20', 'groupId': 'OG001'}, {'value': '0.9605', 'spread': '4', 'groupId': 'OG002'}, {'value': '0.9412', 'spread': '8', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '1.183', 'spread': '22', 'groupId': 'OG000'}, {'value': '1.075', 'spread': '30', 'groupId': 'OG001'}, {'value': '1.142', 'spread': '33', 'groupId': 'OG002'}, {'value': '0.9844', 'spread': '18', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.9744', 'spread': '20', 'groupId': 'OG000'}, {'value': '0.8471', 'spread': '36', 'groupId': 'OG001'}, {'value': '0.9717', 'spread': '18', 'groupId': 'OG002'}, {'value': '0.8712', 'spread': '21', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '10.88', 'spread': '10', 'groupId': 'OG000'}, {'value': '13.47', 'spread': '21', 'groupId': 'OG001'}, {'value': '10.60', 'spread': '49', 'groupId': 'OG002'}, {'value': '13.22', 'spread': '10', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '8.566', 'spread': '14', 'groupId': 'OG000'}, {'value': '11.05', 'spread': '30', 'groupId': 'OG001'}, {'value': '10.13', 'spread': '23', 'groupId': 'OG002'}, {'value': '12.46', 'spread': '9', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'title': 'Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '10.83', 'spread': '15', 'groupId': 'OG000'}, {'value': '16.57', 'spread': '10', 'groupId': 'OG001'}, {'value': '13.12', 'spread': '22', 'groupId': 'OG002'}, {'value': '15.88', 'spread': '29', 'groupId': 'OG003'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '11.60', 'spread': '10', 'groupId': 'OG000'}, {'value': '17.13', 'spread': '8', 'groupId': 'OG001'}, {'value': '14.37', 'spread': '18', 'groupId': 'OG002'}, {'value': '17.32', 'spread': '29', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.', 'unitOfMeasure': 'Liter/hour (L/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable at specified timepoints."}, {'type': 'SECONDARY', 'title': 'Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '200.1', 'spread': '84', 'groupId': 'OG000'}, {'value': '279.6', 'spread': '62', 'groupId': 'OG001'}, {'value': '198.1', 'spread': '98', 'groupId': 'OG002'}, {'value': '186.0', 'spread': '115', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\\*kel).', 'unitOfMeasure': 'Liter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.95', 'spread': '9.3938', 'groupId': 'OG000'}, {'value': '13.01', 'spread': '8.8563', 'groupId': 'OG001'}, {'value': '11.44', 'spread': '6.8367', 'groupId': 'OG002'}, {'value': '8.587', 'spread': '5.8524', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '18.47', 'spread': '16', 'groupId': 'OG000'}, {'value': '96.86', 'spread': '5', 'groupId': 'OG001'}, {'value': '373.2', 'spread': '10', 'groupId': 'OG002'}, {'value': '85.85', 'spread': '20', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 (0 to 12 hours)', 'description': 'Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\\*urine concentration) for each collection over the dosing interval.', 'unitOfMeasure': 'Milligram (mg)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '9.261', 'spread': '16', 'groupId': 'OG000'}, {'value': '16.15', 'spread': '5', 'groupId': 'OG001'}, {'value': '24.90', 'spread': '10', 'groupId': 'OG002'}, {'value': '14.34', 'spread': '20', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 (0 to 12 hours)', 'description': 'Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\\*Aetau/dose.', 'unitOfMeasure': 'Percentage of Dose Excreted', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'OG001', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'OG002', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'OG003', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.074', 'spread': '20', 'groupId': 'OG000'}, {'value': '2.771', 'spread': '5', 'groupId': 'OG001'}, {'value': '3.586', 'spread': '26', 'groupId': 'OG002'}, {'value': '2.477', 'spread': '51', 'groupId': 'OG003'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 10 (0 to 12 hours)', 'description': 'CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.', 'unitOfMeasure': 'Liter/hour (L/hr)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'title': 'AUCinf', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '44140', 'spread': '38', 'groupId': 'OG000'}, {'value': '28430', 'spread': '28', 'groupId': 'OG001'}, {'value': '42930', 'spread': '43', 'groupId': 'OG002'}, {'value': '46170', 'spread': '27', 'groupId': 'OG003'}]}]}, {'title': 'AUClast', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '43570', 'spread': '37', 'groupId': 'OG000'}, {'value': '27750', 'spread': '29', 'groupId': 'OG001'}, {'value': '41620', 'spread': '41', 'groupId': 'OG002'}, {'value': '35930', 'spread': '54', 'groupId': 'OG003'}]}]}], 'analyses': [{'groupIds': ['OG002', 'OG003'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '72.87', 'ciLowerLimit': '60.98', 'ciUpperLimit': '87.09', 'estimateComment': 'A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages', 'groupDescription': 'AUCinf', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '76.45', 'ciLowerLimit': '68.35', 'ciUpperLimit': '85.52', 'estimateComment': 'A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages', 'groupDescription': 'AUCinf', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '73.52', 'ciLowerLimit': '65.70', 'ciUpperLimit': '82.27', 'estimateComment': 'A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages', 'groupDescription': 'AUClast', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '75.16', 'ciLowerLimit': '66.36', 'ciUpperLimit': '85.13', 'estimateComment': 'A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages', 'groupDescription': 'AUClast', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.', 'unitOfMeasure': 'Nanogram*Hour per milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number Analyzed'' signifies participants evaluable for the specified rows. This outcome measure was planned to be analyzed only in the tablet formulation as pre-specified in the protocol."}, {'type': 'SECONDARY', 'title': 'Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '12', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '6934', 'spread': '35', 'groupId': 'OG000'}, {'value': '4590', 'spread': '21', 'groupId': 'OG001'}, {'value': '6284', 'spread': '38', 'groupId': 'OG002'}, {'value': '5008', 'spread': '47', 'groupId': 'OG003'}]}]}], 'analyses': [{'groupIds': ['OG002', 'OG003'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '76.72', 'ciLowerLimit': '60.21', 'ciUpperLimit': '97.75', 'estimateComment': 'A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages', 'nonInferiorityType': 'OTHER'}, {'groupIds': ['OG000', 'OG001'], 'paramType': 'Ratio of Adjusted Geometric Means', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '70.92', 'ciLowerLimit': '53.70', 'ciUpperLimit': '93.67', 'estimateComment': 'A paired t-test was used. Values had been back-transformed from natural log scale. Ratios (and 90% CIs) were expressed as percentages', 'nonInferiorityType': 'OTHER'}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.', 'unitOfMeasure': 'Nanogram per milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the tablet formulation as pre-specified in the protocol.'}, {'type': 'SECONDARY', 'title': 'Part 3: Time for Cmax (Tmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.750', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '1.05'}, {'value': '1.01', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '2.00'}, {'value': '4.00', 'groupId': 'OG002', 'lowerLimit': '1.00', 'upperLimit': '4.00'}, {'value': '1.34', 'groupId': 'OG003', 'lowerLimit': '1.00', 'upperLimit': '2.00'}, {'value': '4.00', 'groupId': 'OG004', 'lowerLimit': '2.00', 'upperLimit': '6.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 3: Maximum Observed Concentration (Cmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '9354', 'spread': '18', 'groupId': 'OG000'}, {'value': '6934', 'spread': '35', 'groupId': 'OG001'}, {'value': '4590', 'spread': '21', 'groupId': 'OG002'}, {'value': '6284', 'spread': '38', 'groupId': 'OG003'}, {'value': '5008', 'spread': '47', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram/milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '42540', 'spread': '35', 'groupId': 'OG000'}, {'value': '43570', 'spread': '37', 'groupId': 'OG001'}, {'value': '27750', 'spread': '29', 'groupId': 'OG002'}, {'value': '41620', 'spread': '41', 'groupId': 'OG003'}, {'value': '35930', 'spread': '54', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '42970', 'spread': '35', 'groupId': 'OG000'}, {'value': '44140', 'spread': '38', 'groupId': 'OG001'}, {'value': '28430', 'spread': '28', 'groupId': 'OG002'}, {'value': '42930', 'spread': '43', 'groupId': 'OG003'}, {'value': '46170', 'spread': '27', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 3: Terminal Half-Life (t1/2) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.578', 'spread': '3.2536', 'groupId': 'OG000'}, {'value': '7.957', 'spread': '3.8740', 'groupId': 'OG001'}, {'value': '10.15', 'spread': '2.2890', 'groupId': 'OG002'}, {'value': '6.822', 'spread': '3.5964', 'groupId': 'OG003'}, {'value': '11.07', 'spread': '4.4518', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 3: Apparent Clearance (CL/F) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.97', 'spread': '35', 'groupId': 'OG000'}, {'value': '13.58', 'spread': '38', 'groupId': 'OG001'}, {'value': '21.09', 'spread': '28', 'groupId': 'OG002'}, {'value': '13.98', 'spread': '43', 'groupId': 'OG003'}, {'value': '12.98', 'spread': '27', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.', 'unitOfMeasure': 'Liter/hour', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '11', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '136.2', 'spread': '55', 'groupId': 'OG000'}, {'value': '136.7', 'spread': '50', 'groupId': 'OG001'}, {'value': '302.2', 'spread': '31', 'groupId': 'OG002'}, {'value': '120.7', 'spread': '55', 'groupId': 'OG003'}, {'value': '192.8', 'spread': '64', 'groupId': 'OG004'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\\*kel).', 'unitOfMeasure': 'Liter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "Pharmacokinetic (PK) parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 3: Number of Participants With TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 3: Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fasted conditions on Day 1 of either Period 1, 2, 3 or 4. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received a single dose of PF-07817883 600 mg crystalline tablet under fed conditions on Day 1 of either Period 1, 2, 3 or 4. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)', 'description': 'Laboratory parameters included: hematology (monocytes/leukocytes \\>1.2\\*ULN \\[%\\], partial thromboplastin time \\>1.1\\*ULN \\[seconds\\]) and urinalysis (urine hemoglobin \\>=1, bacteria \\>20 \\[/lpf\\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension under fasted conditions. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions. An overnight fast for approximately 10 hours was required. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received PF-07817883 600 mg crystalline tablet under fasted conditions. An overnight fast for approximately 10 hours was required. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received PF-07817883 600 mg crystalline tablet under fed conditions. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 3 of each period', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 3: Number of Participants With ECG Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '12', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 3: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension under fasted conditions. An overnight fast for approximately 10 hours was required.'}, {'id': 'OG001', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fasted', 'description': 'Participants received PF-07817883 600 mg spray dried dispersion (SDD) under fasted conditions. An overnight fast for approximately 10 hours was required. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}, {'id': 'OG002', 'title': 'Part 3: PF-07817883 SDD 600 mg (Tablet), Fed', 'description': 'Participants received PF-07817883 600 mg spray dried dispersion (SDD) under fed conditions. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}, {'id': 'OG003', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fasted', 'description': 'Participants received PF-07817883 600 mg crystalline tablet under fasted conditions. An overnight fast for approximately 10 hours was required. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}, {'id': 'OG004', 'title': 'Part 3: PF-07817883 Crystalline 600 mg (Tablet), Fed', 'description': 'Participants received PF-07817883 600 mg crystalline tablet under fed conditions. PF-07817883 was administered approximately 10 minutes after finishing the meal/snack. Participants swallowed PF-07817883 as whole and did not chew prior to swallowing.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 3 of each period', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 4: Time for Cmax (Tmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.500', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '2.00'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 4: Maximum Observed Concentration (Cmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '6791', 'spread': '35', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram/milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '35520', 'spread': '24', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported.'}, {'type': 'SECONDARY', 'title': 'Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '36910', 'spread': '26', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 4: Terminal Half-Life (t1/2) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.882', 'spread': '3.0621', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 4: Apparent Clearance (CL/F) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '16.26', 'spread': '26', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.', 'unitOfMeasure': 'Liter/hour', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '146.7', 'spread': '36', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\\*kel).', 'unitOfMeasure': 'Liter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 4: Number of Participants With TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 4: Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)', 'description': 'Laboratory parameters included: hematology (mean corpuscular volume \\<0.9\\*LLN \\[cubic micrometer {um\\^3}\\], mean corpuscular hemoglobin \\<0.9\\*LLN \\[picograms per cell {pg/cell}\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'title': 'SBP value < 90 mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'SBP change >= 30 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'SBP change >= 30 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'DBP value < 50 mmHg', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'DBP change >= 20 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'DBP change >= 20 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Pulse rate value < 40 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Pulse rate value > 120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 11', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 4: Number of Participants With ECG Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Up to Day 11', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 5: Number of Participants With TEAEs', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 5: Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'Laboratory parameters included: hematology (lymphocytes \\<0.8\\*LLN \\[10\\^3/mm3\\], lymphocytes/leukocytes \\<0.8\\*LLN \\[%\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\]), chemistry (amylase \\>1.5\\*ULN \\[units/liter\\] {U/L}), and urinalysis (urine hemoglobin \\>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'title': 'SBP value < 90 mmHg', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}]}, {'title': 'SBP change >= 30 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'SBP change >= 30 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}]}, {'title': 'DBP value < 50 mmHg', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}]}, {'title': 'DBP change >= 20 mmHg increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'DBP change >= 20 mmHg decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Pulse rate value < 40 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Pulse rate value > 120 bpm', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 5: Number of Participants With ECG Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '13', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}, {'type': 'SECONDARY', 'title': 'Part 5: Time for Cmax (Tmax) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.500', 'groupId': 'OG000', 'lowerLimit': '0.500', 'upperLimit': '1.12'}, {'value': '0.500', 'groupId': 'OG001', 'lowerLimit': '0.500', 'upperLimit': '1.02'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'Tmax of midazolam was reported in this outcome measure.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '92.37', 'spread': '27', 'groupId': 'OG000'}, {'value': '77.46', 'spread': '32', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 5: Terminal Half-Life (t1/2) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.589', 'spread': '1.6566', 'groupId': 'OG000'}, {'value': '6.923', 'spread': '1.9185', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 't1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 5: Apparent Clearance (CL/F) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '53.02', 'spread': '26', 'groupId': 'OG000'}, {'value': '62.60', 'spread': '31', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.', 'unitOfMeasure': 'Liter/hour', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg', 'description': 'Participants received PF-07817883 600 mg oral suspension twice a day (BID) for 10 days (Day 1 morning to Day 10 morning). On Day 10 morning, participants received a single oral dose of 5 mg midazolam administered with PF-07817883.'}, {'id': 'OG001', 'title': 'Midazolam 5 mg', 'description': 'Participants received oral solution of Midazolam 5 mg on Day 1 of either Period 1 or 2.'}], 'classes': [{'categories': [{'measurements': [{'value': '488.5', 'spread': '44', 'groupId': 'OG000'}, {'value': '598.9', 'spread': '45', 'groupId': 'OG001'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\\*kel).', 'unitOfMeasure': 'Liter', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Part 6: Maximum Observed Concentration (Cmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '53160', 'spread': '21', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Nanogram/milliliter (ng/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.'}, {'type': 'SECONDARY', 'title': 'Part 6: Time for Cmax (Tmax) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.00', 'groupId': 'OG000', 'lowerLimit': '0.567', 'upperLimit': '1.50'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.'}, {'type': 'SECONDARY', 'title': 'Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '23', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '248300', 'spread': '17', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol.'}, {'type': 'SECONDARY', 'title': 'Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '253000', 'spread': '17', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.', 'unitOfMeasure': 'Nanogram*hour/milliliter (ng*hr/mL)', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol."}, {'type': 'SECONDARY', 'title': 'Part 6: Terminal Half-Life (t1/2) of PF-07817883', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 6000 mg (Suspension), Fasted', 'description': 'Participants received 6000 mg PF-07817883 oral suspension administered as two split doses of 3000 mg at 0 and 1 hour on Day 1 of either Period 1, 2 or 3 following an overnight fast of at least 10 hours.'}], 'classes': [{'categories': [{'measurements': [{'value': '12.64', 'spread': '7.1787', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.', 'unitOfMeasure': 'Hours', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': "PK parameter set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention and in whom at least 1 of the PK parameters of interest were reported. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure. This outcome measure was planned to be analyzed only in the PF-07817883 6000 mg (suspension), fasted arm, as pre-specified in the protocol."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast', 'description': 'In this cohort (C), participants received a single dose of placebo as an oral suspension in the fasted (fast) state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 milligram (mg) as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG001', 'title': 'P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast', 'description': 'Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG002', 'title': 'P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast', 'description': 'Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG003', 'title': 'P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast', 'description': 'Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG004', 'title': 'P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed', 'description': 'Participants received a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG005', 'title': 'P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed', 'description': 'Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG006', 'title': 'P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed', 'description': 'Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'FG007', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'FG008', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'FG009', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'FG010', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'FG011', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'FG012', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'FG013', 'title': 'Part 3: Treatment Sequence ABCD', 'description': 'Participants received treatments A, B, C and D in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 spray dried dispersion (SDD) 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'FG014', 'title': 'Part 3: Treatment Sequence BCAD', 'description': 'Participants received treatments B, C, A and D in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'FG015', 'title': 'Part 3: Treatment Sequence CABD', 'description': 'Participants received treatments C, A, B and D in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'FG016', 'title': 'Part 3: Treatment Sequence BACE', 'description': 'Participants received treatments B, A, C and E in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'FG017', 'title': 'Part 3: Treatment Sequence ACBE', 'description': 'Participants received treatments A, C, B and E in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'FG018', 'title': 'Part 3: Treatment Sequence CBAE', 'description': 'Participants received treatments C, B, A and E in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'FG019', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}, {'id': 'FG020', 'title': 'Part 5: Treatment Sequence AB', 'description': 'Participants received a single dose of midazolam 5 mg orally on Day 1 of Period 1 followed by a 2-day washout period. In Period 2, participants received PF-07817883 BID orally for 10 days followed by single dose of midazolam 5 mg on Day 10 followed by a washout of at least 7 days.'}, {'id': 'FG021', 'title': 'Part 5: Treatment Sequence BA', 'description': 'In Period 1, participants received PF-07817883 BID orally for 10 days and on Day 10, participants received a single oral dose of 5 mg midazolam administered with PF-07817883 followed by a washout of at least 7 days. In Period 2, participants received a single dose of midazolam 5 mg orally followed by a 2-day washout period.'}, {'id': 'FG022', 'title': 'Part 6: Treatment Sequence ABC', 'description': 'Participants received treatment A, B and C in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'FG023', 'title': 'Part 6: Treatment Sequence BCA', 'description': 'Participants received treatment B, C and A in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.'}, {'id': 'FG024', 'title': 'Part 6: Treatment Sequence CAB', 'description': 'Participants received treatment C, A and B in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'FG025', 'title': 'Part 6: Treatment Sequence BAC', 'description': 'Participants received treatment B, A and C in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'FG026', 'title': 'Part 6: Treatment Sequence ACB', 'description': 'Participants received treatment A, C and B in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'FG027', 'title': 'Part 6: Treatment Sequence CBA', 'description': 'Participants received treatment C, B and A in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.'}], 'periods': [{'title': 'Part (P) 1 Treatment Period 1 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '4'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Washout 1 (up to 5 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG000', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG001', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG002', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG003', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG004', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG005', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 1.', 'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 1 Treatment Period 2 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG000', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG001', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG002', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG003', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG004', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG005', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 1.', 'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Washout 2 (up to 5 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG000', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG001', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG002', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG003', 'numSubjects': '1'}, {'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG004', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG005', 'numSubjects': '1'}, {'comment': 'Participants who started washout 2 of Part 1.', 'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 1: Treatment Period 3 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG000', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG001', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG002', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG003', 'numSubjects': '1'}, {'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG004', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG005', 'numSubjects': '1'}, {'comment': 'Participants who started Period 3 of Part 1.', 'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '3'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 2 (up to 10 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'comment': 'Participants enrolled in Part 2 of the study.', 'groupId': 'FG007', 'numSubjects': '6'}, {'comment': 'Participants enrolled in Part 2 of the study.', 'groupId': 'FG008', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 2 of the study.', 'groupId': 'FG009', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 2 of the study.', 'groupId': 'FG010', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 2 of the study.', 'groupId': 'FG011', 'numSubjects': '1'}, {'comment': 'Participants enrolled in Part 2 of the study.', 'groupId': 'FG012', 'numSubjects': '3'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '6'}, {'groupId': 'FG008', 'numSubjects': '4'}, {'groupId': 'FG009', 'numSubjects': '3'}, {'groupId': 'FG010', 'numSubjects': '4'}, {'groupId': 'FG011', 'numSubjects': '1'}, {'groupId': 'FG012', 'numSubjects': '3'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3 Period 1 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants enrolled in Part 3 of the study.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants enrolled in Part 3 of the study.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants enrolled in Part 3 of the study.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants enrolled in Part 3 of the study.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants enrolled in Part 3 of the study.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants enrolled in Part 3 of the study.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3: Washout 1 (up to 3 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants who started washout 1 of Part 3.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 3.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 3.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 3.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 3.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants who started washout 1 of Part 3.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3: Period 2 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants who started Period 2 of Part 3.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 3.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 3.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 3.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 3.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants who started Period 2 of Part 3.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3: Washout 2 (up to 3 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants who started washout 2 of Part 3.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 3.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 3.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 3.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 3.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants who started washout 2 of Part 3.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3: Period 3 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants who started Period 3 of Part 3.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 3.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 3.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 3.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 3.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants who started Period 3 of Part 3.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3: Washout 3 (up to 3 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants who started washout 3 of Part 3.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants who started washout 3 of Part 3.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants who started washout 3 of Part 3.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants who started washout 3 of Part 3.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants who started washout 3 of Part 3.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants who started washout 3 of Part 3.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 3: Period 4 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'comment': 'Participants who started Period 4 of Part 3.', 'groupId': 'FG013', 'numSubjects': '2'}, {'comment': 'Participants who started Period 4 of Part 3.', 'groupId': 'FG014', 'numSubjects': '2'}, {'comment': 'Participants who started Period 4 of Part 3.', 'groupId': 'FG015', 'numSubjects': '2'}, {'comment': 'Participants who started Period 4 of Part 3.', 'groupId': 'FG016', 'numSubjects': '2'}, {'comment': 'Participants who started Period 4 of Part 3.', 'groupId': 'FG017', 'numSubjects': '2'}, {'comment': 'Participants who started Period 4 of Part 3.', 'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '2'}, {'groupId': 'FG014', 'numSubjects': '2'}, {'groupId': 'FG015', 'numSubjects': '2'}, {'groupId': 'FG016', 'numSubjects': '2'}, {'groupId': 'FG017', 'numSubjects': '2'}, {'groupId': 'FG018', 'numSubjects': '2'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 4 (Day 1 to Day 11)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'comment': 'Participants enrolled in Part 4 of the study.', 'groupId': 'FG019', 'numSubjects': '6'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '5'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '1'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '1'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 5: Sequence AB: Period 1 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'comment': 'Participants enrolled in Part 5 (sequence AB) of the study.', 'groupId': 'FG020', 'numSubjects': '7'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '1'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '1'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 5:SequenceAB:Washout1(Upto 2 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'comment': 'Participants who started washout 1 of Part 5 (sequence AB).', 'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part5:SequenceAB:Period2(up to 10 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'comment': 'Participants who started Period 2 of Part 5 (sequence AB).', 'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part5:Sequence AB:Washout2(up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'comment': 'Participants who started washout 2 of Part 5 (sequence AB).', 'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '6'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part5:Sequence BA:Period1(up to 10 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'comment': 'Participants enrolled in Part 5 (sequence BA) of the study.', 'groupId': 'FG021', 'numSubjects': '7'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '1'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '1'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part5:Sequence BA:Washout1(up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'comment': 'Participants who started washout 1 of Part 5 (sequence BA).', 'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 5: Sequence BA: Period 2 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'comment': 'Participants who started Period 2 of Part 5 (sequence BA).', 'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part5:Sequence BA:Washout2(up to 2 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'comment': 'Participants who started washout 2 of Part 5 (sequence BA).', 'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '6'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 6 Period 1 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'comment': 'Participants enrolled in Part 6 of the study.', 'groupId': 'FG022', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 6 of the study.', 'groupId': 'FG023', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 6 of the study.', 'groupId': 'FG024', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 6 of the study.', 'groupId': 'FG025', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 6 of the study.', 'groupId': 'FG026', 'numSubjects': '4'}, {'comment': 'Participants enrolled in Part 6 of the study.', 'groupId': 'FG027', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '4'}, {'groupId': 'FG023', 'numSubjects': '4'}, {'groupId': 'FG024', 'numSubjects': '4'}, {'groupId': 'FG025', 'numSubjects': '4'}, {'groupId': 'FG026', 'numSubjects': '4'}, {'groupId': 'FG027', 'numSubjects': '4'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 6: Washout 1 (up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'comment': 'Participants who started washout 1 of Part 6.', 'groupId': 'FG022', 'numSubjects': '4'}, {'comment': 'Participants who started washout 1 of Part 6.', 'groupId': 'FG023', 'numSubjects': '4'}, {'comment': 'Participants who started washout 1 of Part 6.', 'groupId': 'FG024', 'numSubjects': '4'}, {'comment': 'Participants who started washout 1 of Part 6.', 'groupId': 'FG025', 'numSubjects': '4'}, {'comment': 'Participants who started washout 1 of Part 6.', 'groupId': 'FG026', 'numSubjects': '4'}, {'comment': 'Participants who started washout 1 of Part 6.', 'groupId': 'FG027', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '4'}, {'groupId': 'FG023', 'numSubjects': '4'}, {'groupId': 'FG024', 'numSubjects': '4'}, {'groupId': 'FG025', 'numSubjects': '4'}, {'groupId': 'FG026', 'numSubjects': '4'}, {'groupId': 'FG027', 'numSubjects': '4'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 6 Period 2 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'comment': 'Participants who started Period 2 of Part 6.', 'groupId': 'FG022', 'numSubjects': '4'}, {'comment': 'Participants who started Period 2 of Part 6.', 'groupId': 'FG023', 'numSubjects': '4'}, {'comment': 'Participants who started Period 2 of Part 6.', 'groupId': 'FG024', 'numSubjects': '4'}, {'comment': 'Participants who started Period 2 of Part 6.', 'groupId': 'FG025', 'numSubjects': '4'}, {'comment': 'Participants who started Period 2 of Part 6.', 'groupId': 'FG026', 'numSubjects': '4'}, {'comment': 'Participants who started Period 2 of Part 6.', 'groupId': 'FG027', 'numSubjects': '4'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '4'}, {'groupId': 'FG023', 'numSubjects': '4'}, {'groupId': 'FG024', 'numSubjects': '3'}, {'groupId': 'FG025', 'numSubjects': '4'}, {'groupId': 'FG026', 'numSubjects': '4'}, {'groupId': 'FG027', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '1'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '1'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '1'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 6: Washout 2 (up to 7 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'comment': 'Participants who started washout 2 of Part 6.', 'groupId': 'FG022', 'numSubjects': '4'}, {'comment': 'Participants who started washout 2 of Part 6.', 'groupId': 'FG023', 'numSubjects': '4'}, {'comment': 'Participants who started washout 2 of Part 6.', 'groupId': 'FG024', 'numSubjects': '3'}, {'comment': 'Participants who started washout 2 of Part 6.', 'groupId': 'FG025', 'numSubjects': '4'}, {'comment': 'Participants who started washout 2 of Part 6.', 'groupId': 'FG026', 'numSubjects': '4'}, {'comment': 'Participants who started washout 2 of Part 6.', 'groupId': 'FG027', 'numSubjects': '3'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '4'}, {'groupId': 'FG023', 'numSubjects': '4'}, {'groupId': 'FG024', 'numSubjects': '3'}, {'groupId': 'FG025', 'numSubjects': '4'}, {'groupId': 'FG026', 'numSubjects': '4'}, {'groupId': 'FG027', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}, {'title': 'Part 6 Period 3 (Day 1)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'comment': 'Participants who started Period 3 of Part 6.', 'groupId': 'FG022', 'numSubjects': '4'}, {'comment': 'Participants who started Period 3 of Part 6.', 'groupId': 'FG023', 'numSubjects': '4'}, {'comment': 'Participants who started Period 3 of Part 6.', 'groupId': 'FG024', 'numSubjects': '3'}, {'comment': 'Participants who started Period 3 of Part 6.', 'groupId': 'FG025', 'numSubjects': '4'}, {'comment': 'Participants who started Period 3 of Part 6.', 'groupId': 'FG026', 'numSubjects': '4'}, {'comment': 'Participants who started Period 3 of Part 6.', 'groupId': 'FG027', 'numSubjects': '3'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '4'}, {'groupId': 'FG023', 'numSubjects': '4'}, {'groupId': 'FG024', 'numSubjects': '3'}, {'groupId': 'FG025', 'numSubjects': '4'}, {'groupId': 'FG026', 'numSubjects': '4'}, {'groupId': 'FG027', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}, {'groupId': 'FG012', 'numSubjects': '0'}, {'groupId': 'FG013', 'numSubjects': '0'}, {'groupId': 'FG014', 'numSubjects': '0'}, {'groupId': 'FG015', 'numSubjects': '0'}, {'groupId': 'FG016', 'numSubjects': '0'}, {'groupId': 'FG017', 'numSubjects': '0'}, {'groupId': 'FG018', 'numSubjects': '0'}, {'groupId': 'FG019', 'numSubjects': '0'}, {'groupId': 'FG020', 'numSubjects': '0'}, {'groupId': 'FG021', 'numSubjects': '0'}, {'groupId': 'FG022', 'numSubjects': '0'}, {'groupId': 'FG023', 'numSubjects': '0'}, {'groupId': 'FG024', 'numSubjects': '0'}, {'groupId': 'FG025', 'numSubjects': '0'}, {'groupId': 'FG026', 'numSubjects': '0'}, {'groupId': 'FG027', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'A total of 94 participants were enrolled across Belgium and United States.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '4', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '3', 'groupId': 'BG012'}, {'value': '2', 'groupId': 'BG013'}, {'value': '2', 'groupId': 'BG014'}, {'value': '2', 'groupId': 'BG015'}, {'value': '2', 'groupId': 'BG016'}, {'value': '2', 'groupId': 'BG017'}, {'value': '2', 'groupId': 'BG018'}, {'value': '6', 'groupId': 'BG019'}, {'value': '7', 'groupId': 'BG020'}, {'value': '7', 'groupId': 'BG021'}, {'value': '4', 'groupId': 'BG022'}, {'value': '4', 'groupId': 'BG023'}, {'value': '4', 'groupId': 'BG024'}, {'value': '4', 'groupId': 'BG025'}, {'value': '4', 'groupId': 'BG026'}, {'value': '4', 'groupId': 'BG027'}, {'value': '94', 'groupId': 'BG028'}]}], 'groups': [{'id': 'BG000', 'title': 'P1: C1: Placebo,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg, Fast', 'description': 'In this cohort (C), participants received a single dose of placebo as an oral suspension in the fasted (fast) state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 milligram (mg) as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG001', 'title': 'P1: C1: PF-07817883 150mg,Fast/Placebo,Fast/PF-07817883 4000mg,Fast', 'description': 'Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG002', 'title': 'P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/Placebo,Fast', 'description': 'Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG003', 'title': 'P1: C1: PF-07817883 150 mg,Fast/PF-07817883 1500mg,Fast/PF-07817883 4000mg,Fast', 'description': 'Participants received a single dose of PF-07817883 150 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 1500 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 4000 mg as an oral suspension in the fasted state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG004', 'title': 'P1: C2: Placebo,Fast/PF-07817883 3000mg,Fast/Placebo,Fed', 'description': 'Participants received a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of placebo as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG005', 'title': 'P1: C2: PF-07817883 500mg,Fast/Placebo,Fast/PF-07817883 500mg,Fed', 'description': 'Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of placebo as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG006', 'title': 'P1: C2: PF-07817883 500mg,Fast/PF-07817883 3000mg,Fast/PF-07817883 500mg,Fed', 'description': 'Participants received a single dose of PF-07817883 500 mg as an oral suspension in the fasted state on Day 1 of Period 1 followed by a single dose of PF-07817883 3000 mg as an oral suspension in the fasted state on Day 1 of Period 2. Participants were administered a single dose of PF-07817883 500 mg as an oral suspension in the fed state on Day 1 of Period 3. There was a washout of at least 5 days between two doses.'}, {'id': 'BG007', 'title': 'Part 2: Placebo (Suspension) BID, Fasted', 'description': 'Participants received placebo oral suspension twice a day (BID) administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'BG008', 'title': 'Part 2: PF-07817883 200 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 200 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 200 mg in the morning under fasted conditions.'}, {'id': 'BG009', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'BG010', 'title': 'Part 2: PF-07817883 1500 mg (Suspension) BID, Fasted', 'description': 'Participants received PF-07817883 1500 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 1500 mg in the morning under fasted conditions.'}, {'id': 'BG011', 'title': 'Part 2: Placebo (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received placebo oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of placebo in the morning under fasted conditions.'}, {'id': 'BG012', 'title': 'Part 2: PF-07817883 600 mg (Suspension) BID, Fasted, Chinese', 'description': 'Chinese participants received PF-07817883 600 mg oral suspension BID administered every 12 hours on Days 1 to 9. On Day 10, participants received only one dose of PF-07817883 600 mg in the morning under fasted conditions.'}, {'id': 'BG013', 'title': 'Part 3: Treatment Sequence ABCD', 'description': 'Participants received treatments A, B, C and D in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 spray dried dispersion (SDD) 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'BG014', 'title': 'Part 3: Treatment Sequence BCAD', 'description': 'Participants received treatments B, C, A and D in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'BG015', 'title': 'Part 3: Treatment Sequence CABD', 'description': 'Participants received treatments C, A, B and D in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment D: Single dose of PF-07817883 SDD 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'BG016', 'title': 'Part 3: Treatment Sequence BACE', 'description': 'Participants received treatments B, A, C and E in Period 1, 2, 3 and 4 respectively. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'BG017', 'title': 'Part 3: Treatment Sequence ACBE', 'description': 'Participants received treatments A, C, B and E in Period 1, 2, 3 and 4 respectively. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'BG018', 'title': 'Part 3: Treatment Sequence CBAE', 'description': 'Participants received treatments C, B, A and E in Period 1, 2, 3 and 4 respectively. Treatment C: Single dose of PF-07817883 600 mg suspension in fasted conditions. Treatment B: Single dose of PF-07817883 crystalline 600 mg tablet in fasted conditions. Treatment A: Single dose of PF-07817883 SDD 600 mg tablets in fasted conditions. Treatment E: Single dose of PF-07817883 crystalline 600 mg tablet in fed conditions. There was a washout of at least 3 days between 2 doses.'}, {'id': 'BG019', 'title': 'Part 4: PF-07817883 600 mg (Suspension), Fasted', 'description': 'Participants received a single dose of PF-07817883 600 mg oral suspension on Day 1 following an overnight fast of approximately 10 hours.'}, {'id': 'BG020', 'title': 'Part 5: Treatment Sequence AB', 'description': 'Participants received a single dose of midazolam 5 mg orally on Day 1 of Period 1 followed by a 2-day washout period. In Period 2, participants received PF-07817883 BID orally for 10 days followed by single dose of midazolam 5 mg on Day 10 followed by a washout of at least 7 days.'}, {'id': 'BG021', 'title': 'Part 5: Treatment Sequence BA', 'description': 'In Period 1, participants received PF-07817883 BID orally for 10 days and on Day 10, participants received a single oral dose of 5 mg midazolam administered with PF-07817883 followed by a washout of at least 7 days. In Period 2, participants received a single dose of midazolam 5 mg orally followed by a 2-day washout period.'}, {'id': 'BG022', 'title': 'Part 6: Treatment Sequence ABC', 'description': 'Participants received treatment A, B and C in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'BG023', 'title': 'Part 6: Treatment Sequence BCA', 'description': 'Participants received treatment B, C and A in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.'}, {'id': 'BG024', 'title': 'Part 6: Treatment Sequence CAB', 'description': 'Participants received treatment C, A and B in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'BG025', 'title': 'Part 6: Treatment Sequence BAC', 'description': 'Participants received treatment B, A and C in Period 1, 2 and 3 respectively. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'BG026', 'title': 'Part 6: Treatment Sequence ACB', 'description': 'Participants received treatment A, C and B in Period 1, 2 and 3 respectively. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Each period was separated by a washout of at least 7 days.'}, {'id': 'BG027', 'title': 'Part 6: Treatment Sequence CBA', 'description': 'Participants received treatment C, B and A in Period 1, 2 and 3 respectively. Treatment C: Single dose of Moxifloxacin 400 mg oral tablet at 0 hour and placebo at 1 hour following an overnight fast of at least 10 hours. Treatment B: Single dose of Placebo oral suspension following an overnight fast of at least 10 hours. Treatment A: PF-07817883 6000 mg oral suspension administered as 2 split doses of 3000 mg at 0 and 1 hour under fasted conditions. Each period was separated by a washout of at least 7 days.'}, {'id': 'BG028', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'categories': [{'title': '18-44 Years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '5', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '2', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '3', 'groupId': 'BG012'}, {'value': '2', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '1', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '2', 'groupId': 'BG017'}, {'value': '2', 'groupId': 'BG018'}, {'value': '4', 'groupId': 'BG019'}, {'value': '4', 'groupId': 'BG020'}, {'value': '3', 'groupId': 'BG021'}, {'value': '3', 'groupId': 'BG022'}, {'value': '4', 'groupId': 'BG023'}, {'value': '4', 'groupId': 'BG024'}, {'value': '3', 'groupId': 'BG025'}, {'value': '3', 'groupId': 'BG026'}, {'value': '4', 'groupId': 'BG027'}, {'value': '64', 'groupId': 'BG028'}]}, {'title': '45-60 Years', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '2', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '2', 'groupId': 'BG014'}, {'value': '1', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '2', 'groupId': 'BG019'}, {'value': '3', 'groupId': 'BG020'}, {'value': '4', 'groupId': 'BG021'}, {'value': '1', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '1', 'groupId': 'BG025'}, {'value': '1', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '29', 'groupId': 'BG028'}]}, {'title': 'Not Disclosed', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '1', 'groupId': 'BG028'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "Data for arm - ''Part 2: Placebo (Suspension) BID, Fasted, Chinese'' is not disclosed to avoid risk of identification and kept under ''Not disclosed'' category.", 'unitOfMeasure': 'Participants'}, {'title': 'Sex/Gender, Customized', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '2', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '2', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '2', 'groupId': 'BG020'}, {'value': '2', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '1', 'groupId': 'BG023'}, {'value': '1', 'groupId': 'BG024'}, {'value': '1', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '19', 'groupId': 'BG028'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '4', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '3', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '2', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '2', 'groupId': 'BG018'}, {'value': '6', 'groupId': 'BG019'}, {'value': '5', 'groupId': 'BG020'}, {'value': '5', 'groupId': 'BG021'}, {'value': '4', 'groupId': 'BG022'}, {'value': '3', 'groupId': 'BG023'}, {'value': '3', 'groupId': 'BG024'}, {'value': '3', 'groupId': 'BG025'}, {'value': '4', 'groupId': 'BG026'}, {'value': '4', 'groupId': 'BG027'}, {'value': '74', 'groupId': 'BG028'}]}, {'title': 'Not Disclosed', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '1', 'groupId': 'BG028'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "Data for arm - ''Part 2: Placebo (Suspension) BID, Fasted, Chinese'' is not disclosed to avoid risk of identification and kept under ''Not disclosed'' category.", 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '1', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '2', 'groupId': 'BG028'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '2', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '3', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '1', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '1', 'groupId': 'BG019'}, {'value': '2', 'groupId': 'BG020'}, {'value': '4', 'groupId': 'BG021'}, {'value': '1', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '1', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '1', 'groupId': 'BG026'}, {'value': '1', 'groupId': 'BG027'}, {'value': '19', 'groupId': 'BG028'}]}, {'title': 'Black or African American', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '3', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '1', 'groupId': 'BG017'}, {'value': '1', 'groupId': 'BG018'}, {'value': '1', 'groupId': 'BG019'}, {'value': '2', 'groupId': 'BG020'}, {'value': '1', 'groupId': 'BG021'}, {'value': '2', 'groupId': 'BG022'}, {'value': '1', 'groupId': 'BG023'}, {'value': '1', 'groupId': 'BG024'}, {'value': '3', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '1', 'groupId': 'BG027'}, {'value': '31', 'groupId': 'BG028'}]}, {'title': 'White', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '4', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '1', 'groupId': 'BG013'}, {'value': '2', 'groupId': 'BG014'}, {'value': '2', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '1', 'groupId': 'BG018'}, {'value': '3', 'groupId': 'BG019'}, {'value': '3', 'groupId': 'BG020'}, {'value': '2', 'groupId': 'BG021'}, {'value': '1', 'groupId': 'BG022'}, {'value': '2', 'groupId': 'BG023'}, {'value': '2', 'groupId': 'BG024'}, {'value': '1', 'groupId': 'BG025'}, {'value': '3', 'groupId': 'BG026'}, {'value': '2', 'groupId': 'BG027'}, {'value': '39', 'groupId': 'BG028'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '1', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '2', 'groupId': 'BG028'}]}, {'title': 'Not Disclosed', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '1', 'groupId': 'BG028'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "Data for arm - ''Part 2: Placebo (Suspension) BID, Fasted, Chinese'' is not disclosed to avoid risk of identification and kept under ''Not disclosed'' category.", 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '4', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '2', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '1', 'groupId': 'BG019'}, {'value': '3', 'groupId': 'BG020'}, {'value': '1', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '3', 'groupId': 'BG023'}, {'value': '2', 'groupId': 'BG024'}, {'value': '2', 'groupId': 'BG025'}, {'value': '2', 'groupId': 'BG026'}, {'value': '2', 'groupId': 'BG027'}, {'value': '33', 'groupId': 'BG028'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}, {'value': '2', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '4', 'groupId': 'BG009'}, {'value': '4', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '3', 'groupId': 'BG012'}, {'value': '2', 'groupId': 'BG013'}, {'value': '2', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '1', 'groupId': 'BG016'}, {'value': '2', 'groupId': 'BG017'}, {'value': '2', 'groupId': 'BG018'}, {'value': '5', 'groupId': 'BG019'}, {'value': '4', 'groupId': 'BG020'}, {'value': '6', 'groupId': 'BG021'}, {'value': '4', 'groupId': 'BG022'}, {'value': '1', 'groupId': 'BG023'}, {'value': '2', 'groupId': 'BG024'}, {'value': '2', 'groupId': 'BG025'}, {'value': '2', 'groupId': 'BG026'}, {'value': '2', 'groupId': 'BG027'}, {'value': '60', 'groupId': 'BG028'}]}, {'title': 'Not Disclosed', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '1', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}, {'value': '0', 'groupId': 'BG013'}, {'value': '0', 'groupId': 'BG014'}, {'value': '0', 'groupId': 'BG015'}, {'value': '0', 'groupId': 'BG016'}, {'value': '0', 'groupId': 'BG017'}, {'value': '0', 'groupId': 'BG018'}, {'value': '0', 'groupId': 'BG019'}, {'value': '0', 'groupId': 'BG020'}, {'value': '0', 'groupId': 'BG021'}, {'value': '0', 'groupId': 'BG022'}, {'value': '0', 'groupId': 'BG023'}, {'value': '0', 'groupId': 'BG024'}, {'value': '0', 'groupId': 'BG025'}, {'value': '0', 'groupId': 'BG026'}, {'value': '0', 'groupId': 'BG027'}, {'value': '1', 'groupId': 'BG028'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "Data for arm - ''Part 2: Placebo (Suspension) BID, Fasted, Chinese'' is not disclosed to avoid risk of identification and kept under ''Not disclosed'' category.", 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the product they actually received.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-03-09', 'size': 1189457, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-09-12T12:20', 'hasProtocol': True}, {'date': '2023-05-24', 'size': 5482633, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-09-12T12:21', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR'], 'maskingDescription': 'PART-1, 2 and 6 are double-blind, sponsor-open while PART-3, 4 and 5 are open label'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'PART-1 and -2 are a randomized, double-blind, sponsor-open, placebo-controlled trial to evaluate safety, tolerability and PK of single and multiple escalating oral doses of PF 07817883 in healthy adult participants, respectively. PART-1 is crossover while PART-2 is parallel cohort study design. PART-2 of the study may also evaluate the safety, tolerability and PK in Japanese and Chinese participants. PART-3 is a randomized, open-label, cross-over, study to evaluate relative bioavailability and food effect of up to 2 new PF 07817883 oral formulations. PART-4 is an open label, non-randomized, single period cohort to evaluate the metabolism and excretion of PF 07817883. PART-5 is an open-label, randomized, cross-over cohort to evaluate the effect of steady state PF-07817883 on PK of midazolam in healthy participants. PART-6 is a sponsor-open, randomized, 3-treatment, 3-period, cross over study to evaluate safety, tolerability, and PK of PF 07817883 at supratherapeutic exposure.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 94}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-10-17', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-09', 'completionDateStruct': {'date': '2023-09-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-09-12', 'studyFirstSubmitDate': '2022-10-11', 'resultsFirstSubmitDate': '2024-09-12', 'studyFirstSubmitQcDate': '2022-10-11', 'lastUpdatePostDateStruct': {'date': '2024-11-21', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-09-12', 'studyFirstPostDateStruct': {'date': '2022-10-14', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-11-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.'}, {'measure': 'Part 1: Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 48 days)', 'description': 'Laboratory parameters included: (lymphocytes less than (\\<) 0.8\\*lower limit of normal \\[LLN\\] \\[10\\^3 per millimeter cube {mm3}\\], lymphocytes/leukocytes \\<0.8\\*LLN \\[percentage {%}\\], neutrophils \\<0.8\\*LLN \\[10\\^3/mm3\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], monocytes/leukocytes greater than (\\>) 1.2\\*upper limit of normal \\[ULN\\] \\[%\\], partial thromboplastin time \\>1.1\\*ULN \\[seconds\\]), chemistry (bicarbonate \\<0.9\\*LLN \\[milliequivalents per liter {mEq/L}\\], creatine kinase \\>2.0\\*ULN \\[units per liter {U/L}\\], lipase \\>1.5\\*ULN \\[U/L\\]), and urinalysis (urine hemoglobin greater than or equal to \\[\\>=\\] 1, leukocyte esterase \\>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Part 1: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'timeFrame': 'Up to Day 2 of each period', 'description': 'Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR) were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value less than (\\<) 90 millimeter of mercury (mmHg), change greater than or equal to (\\>=) 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 beats per minute (bpm), value \\> 120 bpm.'}, {'measure': 'Part 1: Number of Participants With Electrocardiogram (ECG) Abnormalities', 'timeFrame': 'Up to Day 2 of each period', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.'}, {'measure': 'Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.'}, {'measure': 'Part 2: Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 55 days)', 'description': 'Laboratory parameters included: hematology (lymphocytes/leukocytes \\>1.2\\*ULN \\[%\\], neutrophils \\<0.8\\*LLN \\[10\\^3/mm3\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\]), chemistry (urate \\>1.2\\*ULN \\[milligrams per deciliter\\] {mg/dL}), and urinalysis (ketones \\>=1, urine hemoglobin \\>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Part 2: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'timeFrame': 'Up to Day 12', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.'}, {'measure': 'Part 2: Number of Participants With Electrocardiogram (ECG) Abnormalities', 'timeFrame': 'Up to Day 12', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.'}, {'measure': 'Part 3:Ratio Based on Area Under Plasma Concentration Time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) and Area Under Concentration-Time Curve From Time 0 Extrapolated to Infinite Time (AUCinf) of Oral Formulation and Suspension', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of oral formulation and suspension were reported in statistical analysis.'}, {'measure': 'Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Oral Formulation and Suspension', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for Cmax are reported in the descriptive section. Ratio based on Cmax of oral formulation and suspension were reported in statistical analysis.'}, {'measure': 'Part 4: Percentage of Total Dose Administered Recovered in Urine', 'timeFrame': 'Up to 144 hours post-dose', 'description': 'The percentage of total dose administered recovered in urine was reported in this outcome measure.'}, {'measure': 'Part 4: Percentage of Total Dose Administered Recovered in Feces', 'timeFrame': 'Up to 144 hours post-dose', 'description': 'The percentage of total dose administered recovered in feces was reported in this outcome measure.'}, {'measure': 'Part 4: Percentage of Total Dose Administered Recovered in Urine and Feces', 'timeFrame': 'Up to 144 hours post-dose', 'description': 'The percentage of total dose administered recovered in urine and feces was reported in this outcome measure.'}, {'measure': 'Part 5: Maximum Observed Concentration (Cmax) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'Cmax of midazolam was reported in this outcome measure.'}, {'measure': 'Part 5: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'AUCinf of midazolam was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.'}, {'measure': 'Part 6: Number of Participants With TEAEs', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.'}, {'measure': 'Part 6: Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study treatment up to 28-35 days after administration of last dose of study intervention (maximum up to 52 days)', 'description': 'Laboratory parameters included: hematology (lymphocytes \\<0.6\\*LLN \\[10\\^3/mm3\\], lymphocytes/leukocytes \\>1.2\\*ULN \\[%\\], neutrophils \\<0.8\\*LLN \\[10\\^3/mm3\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], basophils/leukocytes \\>1.2\\*ULN \\[%\\], eosinophils/leukocytes \\>1.2\\*ULN \\[%\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\], partial thromboplastin time \\>1.1\\*ULN \\[seconds\\], prothrombin time \\>1.1\\*ULN \\[seconds\\]), chemistry (bicarbonate \\<0.9\\*LLN \\[mEq/L\\], creatine kinase \\> 2.0\\*ULN \\[U/L\\], lipase \\> 1.5\\*ULN \\[U/L\\], urobilinogen \\>=1 \\[ehrlich units/deciliter\\] {EU/dL}) and urinalysis (urine hemoglobin \\>=1, leukocyte esterase \\>=1, ketones \\>=1, bacteria \\>20 \\[per low power field\\] {/lpf}). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Part 6: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'timeFrame': 'Up to Day 6 of each period', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm.'}, {'measure': 'Part 6: Number of Participants According to Categorization of ECG Data', 'timeFrame': 'Up to Day 6 of each period', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured QTcF interval, aggregate 450 milliseconds (msec) \\< value \\<= 480 msec and QTcF interval, aggregate 30 msec \\< change \\<= 60 msec. Number of participants with abnormalities in ECG were reported in this outcome measure.'}], 'secondaryOutcomes': [{'measure': 'Part 1: Maximum Observed Concentration (Cmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 1: Time for Cmax (Tmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 1: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.'}, {'measure': 'Part 1: Dose Normalized Cmax (Cmax[dn]) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.'}, {'measure': 'Part 1: Dose Normalized AUClast (AUClast[dn]) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUClast(dn) of PF-07817883 was reported in this outcome measure. AUClast(dn) was calculated by AUClast/dose.'}, {'measure': 'Part 1: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.'}, {'measure': 'Part 1: Dose Normalized AUCinf (AUCinf[dn]) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUCinf(dn) of PF-07817883 was reported in this outcome measure. AUCinf(dn) was calculated as AUCinf/dose.'}, {'measure': 'Part 1: Terminal Half-Life (t1/2) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.'}, {'measure': 'Part 1: Apparent Volume of Distribution (Vz/F) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\\*kel).'}, {'measure': 'Part 1: Apparent Clearance (CL/F) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.'}, {'measure': 'Part 2: Maximum Observed Concentration (Cmax) of PF-07817883 on Days 1, 5 and 10', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 2: Time for Cmax (Tmax) of PF-07817883 on Days 1, 5 and 10', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 2: Area Under the Plasma Concentration-Time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) of PF-07817883 on Days 1, 5 and 10', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'AUCtau was defined as area under the plasma concentration-time profile from time 0 to time tau, the dosing interval, where tau= 12 hours. AUCtau of PF-07817883 was reported in this outcome measure. AUCtau was calculated by linear/log trapezoidal method.'}, {'measure': 'Part 2: Concentration at 12 Hour Nominal Time Post-Dose (C12) of PF-07817883 on Days 5 and 10', 'timeFrame': '12 hours on Day 5 and Day 10', 'description': 'C12 of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 2: Dose Normalized Cmax (Cmax[dn]) of PF-07817883 on Days 1, 5 and 10', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Cmax(dn) of PF-07817883 was reported in this outcome measure. Cmax(dn) was calculated as Cmax/dose.'}, {'measure': 'Part 2: Dose Normalized AUCtau (AUCtau[dn]) of PF-07817883 on Days 1, 5 and 10', 'timeFrame': 'Day 1 and Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'AUCtau(dn) was defined as dose normalized AUCtau, where tau= 12 hours. AUCtau(dn) of PF-07817883 was reported in this outcome measure. AUCtau(dn) was calculated as AUCtau/dose.'}, {'measure': 'Part 2: Average Concentration (Cav) of PF-07817883 on Days 5 and 10', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'Cav of PF-07817883 was reported in this outcome measure. Cav was calculated as AUCtau/12.'}, {'measure': 'Part 2: Observed Accumulation Ratio for AUCtau (Rac) of PF-07817883 on Days 5 and 10', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose)', 'description': 'Rac was defined as observed accumulation ratio for AUCtau, where tau= 12 hours. Rac of PF-07817883 was reported in this outcome measure. Rac was calculated as AUCtau on Day 5 or Day 10/AUCtau on Day 1.'}, {'measure': 'Part 2: Observed Accumulation Ratio for Cmax (Rac,Cmax) of PF-07817883 on Days 5 and 10', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Rac,Cmax of PF-07817883 was reported in this outcome measure. Rac,Cmax was calculated as Cmax on Day 5 or Day 10/Cmax on Day 1.'}, {'measure': 'Part 2: Peak-to-Trough Ratio (PTR) of PF-07817883 on Days 5 and 10', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'PTR of PF-07817883 was reported in this outcome measure. PTR was calculated as Cmax/Cmin.'}, {'measure': 'Part 2: Apparent Clearance (CL/F) of PF-07817883 on Days 5 and 10', 'timeFrame': 'Day 5 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12 hours post-dose) and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.'}, {'measure': 'Part 2: Apparent Volume of Distribution (Vz/F) of PF-07817883 on Day 10', 'timeFrame': 'Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\\*kel).'}, {'measure': 'Part 2: Terminal Half-Life (t1/2) of PF-07817883 on Day 10', 'timeFrame': 'Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.'}, {'measure': 'Part 2: Amount Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau) of PF-07817883 on Day 10', 'timeFrame': 'Day 10 (0 to 12 hours)', 'description': 'Aetau was defined as amount excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau of PF-07817883 was reported in this outcome measure. Aetau was calculated as sum of (urine volume\\*urine concentration) for each collection over the dosing interval.'}, {'measure': 'Part 2: Percent of Dose Excreted in Urine as Unchanged Drug Over the Dosing Interval Tau (Aetau%) of PF-07817883 on Day 10', 'timeFrame': 'Day 10 (0 to 12 hours)', 'description': 'Aetau% was defined as percentage of dose excreted in urine as unchanged drug over the dosing interval tau, where tau= 12 hours. Aetau% of PF-07817883 was reported in this outcome measure. Aetau% was calculated as 100\\*Aetau/dose.'}, {'measure': 'Part 2: Renal Clearance (CLr) of PF-07817883 on Day 10', 'timeFrame': 'Day 10 (0 to 12 hours)', 'description': 'CLr of PF-07817883 was reported in this outcome measure. CLr was calculated as Aetau/AUCtau.'}, {'measure': 'Part 3: Ratio Based on AUClast and AUCinf of Tablet Formulation Under Fed Condition and Fasted Condition', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for AUClast and AUCinf are reported in the descriptive section. AUClast was calculated by the linear/log trapezoidal method. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis. Ratio based on AUClast and AUCinf of tablet formulations under fed and fasted conditions were reported in statistical analysis.'}, {'measure': 'Part 3: Ratio Based on Maximum Observed Concentration (Cmax) of Tablet Formulation Under Fed Condition and Fasted Condition', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Data for Cmax are reported in the descriptive section. Ratio based on Cmax of tablet formulation under fed and fasted conditions were reported in statistical analysis.'}, {'measure': 'Part 3: Time for Cmax (Tmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 3: Maximum Observed Concentration (Cmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 3: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.'}, {'measure': 'Part 3: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.'}, {'measure': 'Part 3: Terminal Half-Life (t1/2) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.'}, {'measure': 'Part 3: Apparent Clearance (CL/F) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.'}, {'measure': 'Part 3: Apparent Volume of Distribution (Vz/F) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\\*kel).'}, {'measure': 'Part 3: Number of Participants With TEAEs', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.'}, {'measure': 'Part 3: Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 49 days)', 'description': 'Laboratory parameters included: hematology (monocytes/leukocytes \\>1.2\\*ULN \\[%\\], partial thromboplastin time \\>1.1\\*ULN \\[seconds\\]) and urinalysis (urine hemoglobin \\>=1, bacteria \\>20 \\[/lpf\\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Part 3: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'timeFrame': 'Up to Day 3 of each period', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm. 4. Number of participants with vital signs meeting any of the pre-defined criteria is reported in this outcome measure.'}, {'measure': 'Part 3: Number of Participants With ECG Abnormalities', 'timeFrame': 'Up to Day 3 of each period', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.'}, {'measure': 'Part 4: Time for Cmax (Tmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 4: Maximum Observed Concentration (Cmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 4: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.'}, {'measure': 'Part 4: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.'}, {'measure': 'Part 4: Terminal Half-Life (t1/2) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.'}, {'measure': 'Part 4: Apparent Clearance (CL/F) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'CL/F of PF-07817883 was reported in this outcome measure. CL/F was calculated as dose/AUCinf.'}, {'measure': 'Part 4: Apparent Volume of Distribution (Vz/F) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 48, 72 hours post-dose)', 'description': 'Vz/F of PF-07817883 was reported in this outcome measure. Vz/F was calculated as dose/(AUCtau\\*kel).'}, {'measure': 'Part 4: Number of Participants With TEAEs', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.'}, {'measure': 'Part 4: Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study treatment up to 29-36 days after administration of last dose of study intervention (maximum up to 47 days)', 'description': 'Laboratory parameters included: hematology (mean corpuscular volume \\<0.9\\*LLN \\[cubic micrometer {um\\^3}\\], mean corpuscular hemoglobin \\<0.9\\*LLN \\[picograms per cell {pg/cell}\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\]). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Part 4: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'timeFrame': 'Up to Day 11', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm.'}, {'measure': 'Part 4: Number of Participants With ECG Abnormalities', 'timeFrame': 'Up to Day 11', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.'}, {'measure': 'Part 5: Number of Participants With TEAEs', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were considered as TEAEs.'}, {'measure': 'Part 5: Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'Laboratory parameters included: hematology (lymphocytes \\<0.8\\*LLN \\[10\\^3/mm3\\], lymphocytes/leukocytes \\<0.8\\*LLN \\[%\\], neutrophils/leukocytes \\<0.8\\*LLN \\[%\\], monocytes/leukocytes \\>1.2\\*ULN \\[%\\]), chemistry (amylase \\>1.5\\*ULN \\[units/liter\\] {U/L}), and urinalysis (urine hemoglobin \\>=1). Number of participants with any lab test abnormalities meeting the pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Part 5: Number of Participants With Vital Signs Meeting Pre-Defined Criteria', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'Vital signs including SBP, DBP and PR were measured in a supine position after approximately 5 minutes of rest for the participant. Criteria for vital signs included: SBP: value \\< 90 mmHg, change \\>= 30 mmHg increase, change \\>= 30 mmHg decrease; DBP: value \\< 50 mmHg, change \\>= 20 mmHg increase, change \\>= 20 mmHg decrease; PR: value \\< 40 bpm, value \\> 120 bpm.'}, {'measure': 'Part 5: Number of Participants With ECG Abnormalities', 'timeFrame': 'From start of study treatment up to 38-45 days after administration of last dose of study intervention (maximum up to 65 days)', 'description': 'Standard 12 lead ECGs were obtained with the participant in a supine position after at least 5 minutes of rest using an ECG machine that automatically calculated the heart rate and measured PR interval, QT interval, QTcF and QRS complex. Number of participants with abnormalities in ECG were reported in this outcome measure.'}, {'measure': 'Part 5: Time for Cmax (Tmax) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'Tmax of midazolam was reported in this outcome measure.'}, {'measure': 'Part 5: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'AUClast of midazolam was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.'}, {'measure': 'Part 5: Terminal Half-Life (t1/2) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 't1/2 of midazolam was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.'}, {'measure': 'Part 5: Apparent Clearance (CL/F) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'CL/F of midazolam was reported in this outcome measure. CL/F was calculated as dose/AUCinf.'}, {'measure': 'Part 5: Apparent Volume of Distribution (Vz/F) of Midazolam', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for Midazolam 5 mg arm and Day 10 (pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose) for PF-07817883 600 mg (Suspension) BID/ Midazolam 5 mg arm', 'description': 'Vz/F of midazolam was reported in this outcome measure. Vz/F was calculated as dose/(AUCinf\\*kel).'}, {'measure': 'Part 6: Maximum Observed Concentration (Cmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'Cmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 6: Time for Cmax (Tmax) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'Tmax of PF-07817883 was reported in this outcome measure.'}, {'measure': 'Part 6: Area Under Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'AUClast of PF-07817883 was reported in this outcome measure. AUClast was calculated by the linear/log trapezoidal method.'}, {'measure': 'Part 6: Area Under the Concentration -Time Curve From Time Zero (0) Extrapolated to Infinite Time (AUCinf) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 'AUCinf of PF-07817883 was reported in this outcome measure. AUCinf was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis.'}, {'measure': 'Part 6: Terminal Half-Life (t1/2) of PF-07817883', 'timeFrame': 'Day 1 (pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose)', 'description': 't1/2 of PF-07817883 was reported in this outcome measure. t1/2 was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Oral Antiviral', 'COVID-19', 'Protease Inhibitor', 'Mpro', 'PF-07817883'], 'conditions': ['Healthy']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://pmiform.com/clinical-trial-info-request?StudyID=C5091001', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': "The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19. Participants will take PF-07817883 by mouth up to 2 times a day. This study may also evaluate how much PF-07817883 gets into the body when taken as pill. We may study if people's diets can affect this study medicine. We may also examine how PF-07817883 is processed and removed by the human body. Finally, we may look into if PF-07817883 has potential to interact with midazolam.", 'detailedDescription': 'Combined 6-part study. Part-1: Single Ascending dose Part-2: Multiple Ascending Dose Part-3: Relative bioavailability and food effect Part-4: Metabolism and Excretion Part-5: Drug-drug interaction with midazolam Part-6: Supratherapeutic exposure Part-1,2 and 6 are double blind, sponsor open and Part-3,4 and 5 are open label study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Healthy male or female subjects between ages of 18-60 years. Male only in part-4.\n* Body Mass Index (BMI) of 17.5 to 30.5kg/m2; and a total body weight \\>50kg (110lbs). A body weight of \\>45 kg may be considered in selected cases.\n* Japanese subjects who have four Japanese biologic grandparents born in Japan\n* Chinese participants who were born in mainland China and both parents are of the Chinese descent.\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)\n* Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy, intestinal resection).\n* Positive test result for SARS-CoV-2 infection at the time of screening or Day-1.\n* Have received COVID-19 vaccine within 7 days before screening or have received only one of the 2 required doses of COVID-19 vaccine\n* Use of tobacco or nicotine containing products in excess of the equivalents of 5 cigarettes per day or 2 chews of tobacco per day\n* Use of prescription or nonprescription drugs and dietary and herbal supplements within 28 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.'}, 'identificationModule': {'nctId': 'NCT05580003', 'briefTitle': 'A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'COVID-19: A MULTIPART, PHASE 1 STUDY WITH RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE-DOSE ESCALATION TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07817883 AND OPTIONAL OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF SOLID ORAL FORMULATION AND OPTIONAL OPEN-LABEL, NON-RANDOMIZED STUDY TO EVALUATE METABOLISM AND EXCRETION OF PF-07817883 AND OPTIONAL RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE EFFECT OF PF-07817883 ON PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY ADULT PARTICIPANTS', 'orgStudyIdInfo': {'id': 'C5091001'}, 'secondaryIdInfos': [{'id': '2022-002871-12', 'type': 'EUDRACT_NUMBER'}, {'id': '2022-002871-12', 'type': 'REGISTRY', 'domain': 'CTIS (EU)'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Dose 1 in PART-1', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Dose 2 in PART-1', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Dose 3 in PART-1', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Dose 4 in PART-1', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Dose 5 in PART-1', 'description': 'Optional dose levels', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Dose 6 in PART-1', 'description': 'Optional dose levels', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo in PART-1', 'description': 'A single dose of placebo', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 DR1 in PART-2', 'description': 'DR=Dosing regimen; twice a day', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 DR2 in PART-2', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 DR3 in PART-2', 'description': 'Optional dosing regimen', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 DR4 in PART-2', 'description': 'Optional dosing regimen', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 in Japanese in PART-2', 'description': 'Optional dosing regimen to be studied in Japanese population', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 in Chinese in PART-2', 'description': 'Optional dosing regimen to be studied in Chinese population', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo in PART-2', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 Suspension Fasted in PART-3', 'description': 'PART-3 is optional', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 FORM-1 Fasted in PART-3', 'description': 'First solid oral formulation (FORM1)', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 FORM-2 Fasted in PART-3', 'description': 'Second solid oral formulations (FORM-2) is optional', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 FORM-1 Fed in PART-3', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 FORM-2 Fed in PART-3', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 in PART-4', 'description': 'PART-4 is optional', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'Midazolam 5 mg in PART-5', 'description': 'Single dose of 5 mg alone', 'interventionNames': ['Drug: Midazolam']}, {'type': 'EXPERIMENTAL', 'label': 'Midazolam 5 mg with PF-07817883 in PART-5', 'description': 'Single dose of 5 mg on Day 10 with multiple doses (twice a day) of PF-07817883', 'interventionNames': ['Drug: PF-07817883', 'Drug: Midazolam']}, {'type': 'EXPERIMENTAL', 'label': 'PF-07817883 in PART-6', 'description': 'A single dose at supratherapeutic exposure administered as divided doses (1h apart)', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo in PART-6', 'description': 'A single dose of placebo administered as divided doses (1h apart)', 'interventionNames': ['Drug: Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Moxifloxacin 400 mg in PART-6 (open label)', 'description': 'Moxifloxacin 400 mg at 0h followed by placebo at 1h', 'interventionNames': ['Drug: Placebo', 'Drug: Moxifloxacin']}], 'interventions': [{'name': 'PF-07817883', 'type': 'DRUG', 'description': 'Oral suspension or solid oral formulation(s)', 'armGroupLabels': ['Midazolam 5 mg with PF-07817883 in PART-5', 'PF-07817883 DR1 in PART-2', 'PF-07817883 DR2 in PART-2', 'PF-07817883 DR3 in PART-2', 'PF-07817883 DR4 in PART-2', 'PF-07817883 Dose 1 in PART-1', 'PF-07817883 Dose 2 in PART-1', 'PF-07817883 Dose 3 in PART-1', 'PF-07817883 Dose 4 in PART-1', 'PF-07817883 Dose 5 in PART-1', 'PF-07817883 Dose 6 in PART-1', 'PF-07817883 FORM-1 Fasted in PART-3', 'PF-07817883 FORM-1 Fed in PART-3', 'PF-07817883 FORM-2 Fasted in PART-3', 'PF-07817883 FORM-2 Fed in PART-3', 'PF-07817883 Suspension Fasted in PART-3', 'PF-07817883 in Chinese in PART-2', 'PF-07817883 in Japanese in PART-2', 'PF-07817883 in PART-4', 'PF-07817883 in PART-6']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo suspension', 'armGroupLabels': ['Moxifloxacin 400 mg in PART-6 (open label)', 'Placebo in PART-1', 'Placebo in PART-2', 'Placebo in PART-6']}, {'name': 'Midazolam', 'type': 'DRUG', 'description': 'midazolam oral solution', 'armGroupLabels': ['Midazolam 5 mg in PART-5', 'Midazolam 5 mg with PF-07817883 in PART-5']}, {'name': 'Moxifloxacin', 'type': 'DRUG', 'description': 'Moxifloxacin 400 mg tablet', 'armGroupLabels': ['Moxifloxacin 400 mg in PART-6 (open label)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06511', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'New Haven Clinical Research Unit', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': 'B-1070', 'city': 'Brussels', 'state': 'Bruxelles-capitale, Région de', 'country': 'Belgium', 'facility': 'Pfizer Clinical Research Unit - Brussels', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}